Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Exagen (XGN) Other Working Capital Changes (2022 - 2025)

Historic Other Working Capital Changes for Exagen (XGN) over the last 4 years, with Q3 2025 value amounting to -$275000.0.

  • Exagen's Other Working Capital Changes fell 1224.49% to -$275000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was -$1.1 million, marking a year-over-year decrease of 1048.81%. This contributed to the annual value of -$976000.0 for FY2024, which is 336.63% up from last year.
  • Exagen's Other Working Capital Changes amounted to -$275000.0 in Q3 2025, which was down 1224.49% from -$270000.0 recorded in Q2 2025.
  • Over the past 5 years, Exagen's Other Working Capital Changes peaked at -$155000.0 during Q1 2022, and registered a low of -$275000.0 during Q3 2025.
  • In the last 4 years, Exagen's Other Working Capital Changes had a median value of -$245000.0 in 2024 and averaged -$243200.0.
  • As far as peak fluctuations go, Exagen's Other Working Capital Changes tumbled by 6129.03% in 2023, and later surged by 625.0% in 2024.
  • Over the past 4 years, Exagen's Other Working Capital Changes (Quarter) stood at -$241000.0 in 2022, then decreased by 0.83% to -$243000.0 in 2023, then dropped by 5.35% to -$256000.0 in 2024, then dropped by 7.42% to -$275000.0 in 2025.
  • Its Other Working Capital Changes stands at -$275000.0 for Q3 2025, versus -$270000.0 for Q2 2025 and -$263000.0 for Q1 2025.